Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy, Immunogenicity and Safety of the 9vHPV Vaccine in Japanese Males
NCT04635423Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2020
- Primary completion
- Dec 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, genital warts and anal neoplasms (4 arms), sponsored by Merck & Co. Primary endpoints: Combined Incidence of Human Papillomavirus (HPV) 6/11/16/18-related Anogenital Persistent Infection at 36 months, Percentage of Participants With Solicited Injection-site Adverse Events (AEs) at 5 days and 3 more. Started Nov 2020; status: completed.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectiongenital wartsanal neoplasms
Beyond the preview
Go deeper on NCT04635423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04635423.